Literature DB >> 1563015

Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumour.

G Acerbis1, L Cleris, M Rodolfo, G Parmiani, F Formelli.   

Abstract

The efficacy of the association of recombinant interleukin-2 (rIL-2) with chemotherapy has been investigated on an experimental model representative of clinical tumours, i.e. on post-surgical spontaneous metastases of a non-immunogenic tumour. We used the M5076 ovarian reticulum cell sarcoma, which metastasizes to the liver after intra-footpad implantation. Such a tumour appeared to be non-immunogenic by a variety of commonly used in vivo assays. Four clinically widely employed drugs, i.e. doxorubicin, cis-diamminedichloroplatinum II, cyclophosphamide and 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU), were tested and BCNU proved to be the most effective one when administered as single injection at the maximum tolerated dose (33 mg/kg i.p.) 1 day after tumour excision. When moderate doses of rIL-2 (6 x 10(5) IU in three injections per day for 5 days) were administered at three different intervals after BCNU, namely before the nadir of white blood cells (1 day after BCNU), at the nadir (3 days after BCNU) or at recovery (6 days after BCNU), no increase in BCNU antitumour activity was observed. The same results were obtained by administering rIL-2 for 5 days before BCNU. Higher doses of rIL-2 (1.2 x 10(6) IU in three injections per day for 5 days), which were always well tolerated in sham-excised non-tumour-bearing mice, proved lethal in two out of four experiments in tumour-bearing animals. In the two experiments in which no lethality was observed, the administration of high doses of rIL-2 1 or 6 days after BCNU significantly increased the antitumour activity of BCNU alone. rIL-2 alone was not active even when administered at high doses. These results indicate that high but not moderate doses of rIL-2 may increase the activity of BCNU against a non-immunogenic tumour. Moreover, they suggest that rIL-2 tolerability is reduced in tumour-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563015     DOI: 10.1007/bf01741748

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  IL-2 induces pulmonary edema and vasoconstriction independent of circulating lymphocytes.

Authors:  T J Ferro; A Johnson; J Everitt; A B Malik
Journal:  J Immunol       Date:  1989-03-15       Impact factor: 5.422

2.  Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type.

Authors:  E Kedar; R Ben-Aziz; E Epstein; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Studies of the mechanisms of toxicity of the administration of recombinant tumor necrosis factor alpha in normal and tumor-bearing mice.

Authors:  J A Krosnick; J K McIntosh; J J Mulé; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients.

Authors:  A Kasid; E P Director; S A Rosenberg
Journal:  J Immunol       Date:  1989-07-15       Impact factor: 5.422

7.  Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes.

Authors:  P Allavena; M Grandi; M D'Incalci; O Geri; F C Giuliani; A Mantovani
Journal:  Int J Cancer       Date:  1987-07-15       Impact factor: 7.396

8.  Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.

Authors:  M Z Papa; J C Yang; J T Vetto; E Shiloni; A Eisenthal; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

9.  Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model.

Authors:  A M Eggermont; P H Sugarbaker
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.